1. Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A
- Author
-
Jian-Guang Luo, Si-Bei Wang, Chen Chen, Dong-Rong Zhu, Hao Zhang, Xiao-Qin Liu, Ling-Yi Kong, and Jiang-Min Zhu
- Subjects
STAT3 Transcription Factor ,Phosphatase ,Protein tyrosine phosphatase ,Article ,Stat3 Signaling Pathway ,Cell Line, Tumor ,Humans ,JAK/STAT3 ,STAT3 ,ComputingMethodologies_COMPUTERGRAPHICS ,Cell Proliferation ,Janus Kinases ,Osteosarcoma ,Multidisciplinary ,biology ,Cell growth ,Chemistry ,Protein Tyrosine Phosphatase, Non-Receptor Type 6 ,Cell cycle ,Xenograft Model Antitumor Assays ,Tubocapsenolide A ,SHP-2 ,STAT protein ,biology.protein ,Cancer research ,Protein Tyrosine Phosphatases ,Janus kinase - Abstract
Graphical abstract, Introduction Previously, we have reported a withanolide-type steroid, named tubocapsenolide A (TA), which shows potent anti-proliferative activity in several cancer cell lines. However, its inhibitory effect on the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathway and therapeutic potential on osteosarcoma have not been reported. Objectives In the present study, we aimed to investigate the effect and molecular mechanism of TA in osteosarcoma. Methods The biological functions of TA in U2OS cells were investigated using colony formation, 5-ethynyl-20-deoxyuridine (EDU) staining, and cell cycle/apoptosis assays. The interaction between TA and Src homology 2 phosphatase 2 (SHP-2) was detected by enzyme activity and validated by target-identification methods such as drug affinity responsive target stability (DARTS), cellular thermal shift assay (CETSA), and biolayer interferometry (BLI). The in vivo anti-tumor efficacy of TA was analyzed in the xenograft tumor model. Western blotting analysis was performed to detect the protein expression levels. Results TA exhibited antitumor activity against osteosarcoma both in vitro and in vivo by regulating the JAK/STAT3 signaling pathway. Mechanically, TA interacted with SHP-2 directly and activated its phosphatase activity. Importantly, protein tyrosine phosphatase (PTP) inhibitor, SHP-2 inhibitor, and SHP-2 siRNA could reverse the inhibitory effect of TA on the JAK/STAT3 signaling pathway and restored the TA-induced cell death. Conclusion TA activated the phosphatase activity of SHP-2, which resulted in the inhibition of the JAK/STAT3 pathway and contributed to the antitumor efficacy of TA. Collectively, these findings suggested that TA could serve as a novel therapeutic agent for the treatment of osteosarcoma.
- Published
- 2021
- Full Text
- View/download PDF